Law firm Lowey Dannenberg is investigating ADMA Biologics for potential securities law violations following a Culper Research report alleging channel stuffing practices. The report claims ADMA induced distributors to overstock ASCENIV through rebates and extended payment terms to artificially inflate 2025 revenue growth from -3% actual to +20% reported.

Law firm Bragar Eagel & Squire is investigating ADMA Biologics following a Culper Research short report alleging the company engaged in channel stuffing to inflate revenue growth. The report claims ADMA's actual 2025 revenues declined 3% despite reported 20% growth. ADMA's stock fell 16.63% to $11.33 per share following the report's publication on March 24, 2026.

Pomerantz LLP is investigating ADMA Biologics for potential securities fraud following a Culper Research short report alleging channel stuffing and inflated revenue growth. The report claimed ADMA's 2025 revenues actually declined 3% versus the reported 20% growth. ADMA's stock fell 16.63% on March 24, 2026, and another 13.91% on March 26 following a Cantor Fitzgerald downgrade citing inadequate response to the allegations.

ADMA Biologics is under investigation for potential securities fraud after Culper Research alleged the company engaged in channel stuffing to artificially inflate its 2025 revenue growth from -3% to reported +20%. The allegations caused ADMA's stock to plummet 29% over two trading days, dropping from $13.59 to $9.63 per share on March 24-25, 2026.

Kirby McInerney LLP is investigating ADMA Biologics for potential securities law violations following a Culper Research report alleging channel stuffing and undisclosed related party distribution practices. The report claims ADMA induced distributors to stock excess ASCENIV products through rebates and extended payment terms to artificially inflate 2025 growth figures. ADMA shares declined 17% on March 24, 2026, dropping from $13.59 to $11.33 per share following the allegations.

ADMA Biologics shares plummeted 16% on March 24, 2026, following a short seller report alleging channel stuffing and improper revenue recognition. Culper Research claimed ADMA inflated 2025 revenues by offering rebates and extended payment terms to distributors, with actual growth being -3.5% rather than the reported +20%. The investigation also alleges undisclosed related party sales. Hagens Berman is investigating potential securities law violations.

A securities fraud investigation has been launched into ADMA Biologics following allegations by Culper Research of channel stuffing and undisclosed related party distribution practices. The report claims ADMA induced distributors to stock excess inventory through rebates and extended payment terms to artificially inflate 2025 growth figures. ADMA's stock fell 29.1% over two trading days to $9.63 per share following the announcement.

Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.

The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.

ADMA Biologics will report its second quarter 2025 financial results on August 6, 2025, after market close, with a conference call to discuss financial performance and company updates.

Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.

ADMA Biologics, a U.S.-based biopharmaceutical company, has reiterated its strategic advantage through fully domestic manufacturing, commercialization, and supply chain operations. The company's vertically integrated U.S.-based infrastructure ensures supply chain robustness, regulatory compliance, and alignment with federal and private sector preferences for U.S.-made products.